| 1. |
- Ameur, Adam, et al.
(författare)
-
Single-Molecule Sequencing : Towards Clinical Applications
- 2019
-
Ingår i: Trends in Biotechnology. - : Elsevier BV. - 0167-7799 .- 1879-3096. ; 37:1, s. 72-85
-
Forskningsöversikt (refereegranskat)abstract
- In the past several years, single-molecule sequencing platforms, such as those by Pacific Biosciences and Oxford Nanopore Technologies, have become available to researchers and are currently being tested for clinical applications. They offer exceptionally long reads that permit direct sequencing through regions of the genome inaccessible or difficult to analyze by short-read platforms. This includes disease-causing long repetitive elements, extreme GC content regions, and complex gene loci. Similarly, these platforms enable structural variation characterization at previously unparalleled resolution and direct detection of epigenetic marks in native DNA. Here, we review how these technologies are opening up new clinical avenues that are being applied to pathogenic microorganisms and viruses, constitutional disorders, pharmaco-genomics, cancer, and more.
|
|
| 2. |
- Bajhaiya, Amit K., et al.
(författare)
-
Transcriptional Engineering of Microalgae : Prospects for High-Value Chemicals
- 2017
-
Ingår i: Trends in Biotechnology. - : Elsevier BV. - 0167-7799 .- 1879-3096. ; 35:2, s. 95-99
-
Tidskriftsartikel (refereegranskat)abstract
- Microalgae are diverse microorganisms that are of interest as novel sources of metabolites for various industrial, nutritional, and pharmaceutical applications. Recent studies have demonstrated transcriptional engineering of some metabolic pathways. We propose here that transcriptional engineering could be a viable means to manipulate the biosynthesis of specific high-value metabolic products.
|
|
| 3. |
- Campbell, Kate, 1987, et al.
(författare)
-
The Impact of Systems Biology on Bioprocessing
- 2017
-
Ingår i: Trends in Biotechnology. - : Elsevier BV. - 0167-7799 .- 1879-3096. ; 35:12, s. 1156-1168
-
Forskningsöversikt (refereegranskat)abstract
- Bioprocessing offers a sustainable and green approach to the production of chemicals. However, a bottleneck in introducing bioprocesses is cell factory development, which is costly and time-consuming. A systems biology approach can expedite cell factory design by using genome-wide analyses alongside mathematical modeling to characterize and predict cellular physiology. This approach can drive cycles of design, build, test, and learn implemented by metabolic engineers to optimize the cell factory performance. Streamlining of the design phase requires a clearer understanding of metabolism and its regulation, which can be achieved using quantitative and integrated omic characterization, alongside more advanced analytical methods. We discuss here the current impact of systems biology and challenges of closing the gap between bioprocessing and more traditional methods of chemical production.
|
|
| 4. |
- Eriksson, Dennis, et al.
(författare)
-
A Welcome Proposal to Amend the GMO Legislation of the EU
- 2018
-
Ingår i: Trends in Biotechnology. - : Elsevier BV. - 0167-7799 .- 1879-3096. ; 36, s. 1100-1103
-
Annan publikation (refereegranskat)abstract
- Is the European Union (EU) regulatory framework for genetically modified organisms (GMOs) adequate for emerging techniques, such as genome editing? This has been discussed extensively for more than 10 years. A recent proposal from The Netherlands offers a way to break the deadlock. Here, we discuss how the proposal would affect examples from public plant research.
|
|
| 5. |
|
|
| 6. |
- Ferreira, Raphael, 1990, et al.
(författare)
-
Tackling Cancer with Yeast-Based Technologies
- 2019
-
Ingår i: Trends in Biotechnology. - : Elsevier BV. - 0167-7799 .- 1879-3096. ; 37:6, s. 592-603
-
Forskningsöversikt (refereegranskat)abstract
- The ability to precisely engineer yeast, coupled with its genetic and metabolic similarity to tumor cells, has enabled researchers to use this organism in cancer research. Here we review advances that leveraged yeast as a model organism for studying cancer biology, including the investigation of tumorigenic mechanisms, development of advanced technologies for drug discovery, production of anticancer drugs on an industrial scale, and delivering the next generation of immunotherapies.
|
|
| 7. |
- Loo, Jacky F. C., et al.
(författare)
-
Integrated Printed Microfluidic Biosensors
- 2019
-
Ingår i: Trends in Biotechnology. - : ELSEVIER SCIENCE LONDON. - 0167-7799 .- 1879-3096. ; 37:10, s. 1104-1120
-
Forskningsöversikt (refereegranskat)abstract
- Integrated printed microfluidic biosensors are one of the most recent point-of-care (POC) sensor developments. Fast turnaround time for production and ease of customization, enabled by the integration of recognition elements and transducers, are key for on-site biosensing for both healthcare and industry and for speeding up translation to real-life applications. Here, we provide an overview of recent progress in printed microfluidics, from the 2D to the 4D level, accompanied by novel sensing element integration. We also explore the latest trends in integrated printed microfluidics for healthcare, especially POC diagnostics, and food safety applications.
|
|
| 8. |
- Norouzitallab, Parisa, et al.
(författare)
-
Teaching Shrimps Self-Defense to Fight Infections
- 2019
-
Ingår i: Trends in Biotechnology. - : Elsevier BV. - 0167-7799 .- 1879-3096. ; 37, s. 16-19
-
Annan publikation (refereegranskat)abstract
- A paradigm shift in our understanding of shrimp immunity offers the potential to develop novel disease-control strategies. We summarize cutting-edge findings on the phenomenon of trained immunity in shrimps and discuss how it may contribute to new avenues for controlling disease in these aqua culturally important animals.
|
|
| 9. |
- Shakya, Akhilesh Kumar, et al.
(författare)
-
Antigen-Specific Tolerization and Targeted Delivery as Therapeutic Strategies for Autoimmune Diseases
- 2018
-
Ingår i: Trends in Biotechnology. - Cambridge, MA : Elsevier. - 0167-7799 .- 1879-3096. ; 36:7, s. 686-699
-
Forskningsöversikt (refereegranskat)abstract
- The prevalence of autoimmune disorders is increasing steadily and there is no permanent cure available. Immunomodulation through repeated exposure of antigens, known as antigen-specific immune tolerance or antigen-specific immunotherapy (ASI), is a promising approach to treat or prevent autoimmune disorders. Different optimization protocols (immunization routes, delivery systems, and approaches) are being developed to implement ASI against self-proteins. Including appropriate adjuvants, altered peptide ligand, and using multipeptides are approaches that can be used to specifically target autoimmunity. This review explores various ASI application methods, including different routes of antigen-specific sensitization, delivery systems, immunomodulators containing specific antigens, and other targeted approaches that have been successfully demonstrated to have therapeutic effects on autoimmune diseases. © 2018 Elsevier Ltd.
|
|
| 10. |
- Ståhl, Stefan, et al.
(författare)
-
Affibody Molecules in Biotechnological and Medical Applications
- 2017
-
Ingår i: Trends in Biotechnology. - : Elsevier. - 0167-7799 .- 1879-3096. ; 35:8, s. 691-712
-
Forskningsöversikt (refereegranskat)abstract
- Affibody molecules are small (6.5-kDa) affinity proteins based on a three-helix bundle domain framework. Since their introduction 20 years ago as an alternative to antibodies for biotechnological applications, the first therapeutic affibody molecules have now entered clinical development and more than 400 studies have been published in which affibody molecules have been developed and used in a variety of contexts. In this review, we focus primarily on efforts over the past 5 years to explore the potential of affibody molecules for medical applications in oncology, neurodegenerative, and inflammation disorders, including molecular imaging, receptor signal blocking, and delivery of toxic payloads. In addition, we describe recent examples of biotechnological applications, in which affibody molecules have been exploited as modular affinity fusion partners.
|
|
